GRAIL Inc (GRAL)

Several events impacted GRAIL, Inc.'s stock price between October 2025 and April 2026. Samsung made a $110 million equity investment, and the company completed a $325 million private placement in October 2025. GRAIL presented at the TD Cowen 46th Annual Health Care Conference in February 2026. Josh Ofman was appointed CEO in March 2026. GRAIL integrated its Galleri test into the Epic Electronic Health Record Platform and partnered with Superpower in early April 2026. The company's stock experienced a significant drop of approximately 50% in February 2026. As of April 10, 2026, GRAIL's stock price was $45.63, with a 52-week high of $118.84 and a low of $21.80.

Information regarding the specific demand seasonality for GRAIL, Inc.'s products and services is not explicitly available. Demand may be influenced by healthcare screening cycles, insurance coverage changes, and public health initiatives rather than traditional seasonal consumer patterns.

GRAIL, Inc. is a biotechnology company focused on early cancer detection through its multi-cancer early detection (MCED) blood test, Galleri. The company develops and commercializes technologies for early cancer detection, utilizing a targeted methylation-based platform to analyze blood samples for cancer signals. GRAIL also provides diagnostic aid for cancer tests and development services for clinical studies, pilot testing, research, and therapy development. Josh Ofman was appointed CEO in March 2026, succeeding Bob Ragusa, and Harpal Kumar serves as President, Europe.

GRAIL, Inc. is headquartered in Menlo Park, California, and maintains additional locations in Washington, D.C., North Carolina, and the United Kingdom. The company provides its multi-cancer early detection testing and services in the United States and internationally.

GRAIL's brand reputation has seen both positive developments and scrutiny in the past year. The Galleri test is promoted as a groundbreaking advance, but an NHS England trial was described as overhyped. The company's journey to independence was marked by regulatory challenges, as the European Commission ordered Illumina to divest GRAIL. Positive news includes the integration of the Galleri test into the Epic Electronic Health Record Platform and a partnership with Superpower. There have also been mentions of lawsuits related to stock drops.

Following its spin-off from Illumina in June 2024, Illumina retained a 14.5% minority share in GRAIL, Inc. In October 2025, Samsung took a $110 million equity stake in GRAIL.